The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus - Wikidata - wikimedia - TriplyDB

The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus

The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus

http://www.wikidata.org/entity/Q35286089

about

Lactate Levels with Chronic Metformin Use: A Narrative Review.The clinical utility of pharmacometric models.Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells.

P2860

Q38637898-9324BAA3-E03E-4243-A540-9B4A9C504B39 Q52594703-6AB15B68-D57A-4882-8D50-B7B7E0B1B484 Q55065110-FDEC69C5-88CC-4D89-B694-CDAB7B254129

P2860

The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus

http://www.wikidata.org/entity/Q35286089

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@ast

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@en

type

label

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@ast

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@en

prefLabel

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@ast

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@en

P1433

Q35286089-55331ABC-39EB-496E-A47D-890C2E6EA525

P1476

Q35286089-F67563A6-68A2-4499-9B0C-274BBA8FF84A

P2093

Q35286089-23397377-5206-4721-94D4-C4C9BAA2F438

Q35286089-8463C1E7-8A0A-433F-8555-4C1BAC622A82

Q35286089-9556FE64-47DF-4729-9A22-D88884D2A954

Q35286089-ABF496F7-0D2A-4753-898B-BDFE261C70F7

P2860

Q35286089-0363E118-402F-422B-B237-94A494FDA284

Q35286089-1DAE58E7-0466-46F1-AD37-2C420981DEA3

Q35286089-213F42D6-E2BB-43EC-B153-760C633E8B8D

Q35286089-502912E7-000D-4A9E-B470-3BCFBCCFCD06

Q35286089-5774A68C-655C-4212-9881-376C40EBF157

Q35286089-67BA50A8-09BA-47AA-9404-39B0DD4917A4

Q35286089-77156B39-7A74-48E9-8C0A-446FB7916D82

Q35286089-7EE83AA9-3A37-4C5C-9E01-A1875C842345

Q35286089-8A278F59-579B-49AC-A0B2-42B48CBA0545

Q35286089-98DA13FA-D234-4A82-9B17-72A1023C11F6

P304

Q35286089-6404AEDC-F2E1-4CB3-839D-9392A1773D28

P31

Q35286089-DB11CBFD-7259-485C-A26F-A57CF234FDC0

P356

Q35286089-A0D64022-BB38-40C7-BE46-E948D7F458D5

P407

Q35286089-749972F1-2685-40F2-BDB9-803E26F89B65

P433

Q35286089-E17CD0F2-EACE-42EB-9B7B-68FEC4448CA9

P478

Q35286089-8E6196F5-0EE7-4906-A16A-C4F3BF0E9D98

P50

Q35286089-1808959A-407D-4DE3-A17E-5149F2E98A75

Q35286089-47F79F05-C623-497C-A89F-CD1787BF7B60

Q35286089-65351BCE-9B59-4C29-8D9F-1C4FC1E952EF

Q35286089-FB15B3FD-6BEA-4249-823E-42CC178EE698

P577

Q35286089-9F3B0857-8FF0-4A90-9711-52E262B5FD0F

P698

Q35286089-1CDF2354-186D-4CCB-995B-194B5A14B0AF

P921

Q35286089-20E8B880-D844-493D-BA99-242B2B28FBFF

Q35286089-33659CFE-6A1E-4AE3-9BB7-8BA05438110A

P932

Q35286089-53C60071-263A-4189-B996-80290EA11821

P356

P1433

British Journal of Clinical Pharmacology

P1476

The pharmacokinetics of metfor ...... with type 2 diabetes mellitus

@en

P2093

Garry G Graham

http://www.w3.org/2001/XMLSchema#string

Ken M Williams

http://www.w3.org/2001/XMLSchema#string

Richard O Day

http://www.w3.org/2001/XMLSchema#string

Timothy J Furlong

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of type 2 diabetes in Aboriginal Australians: an 11-year prospective cohort study

Clinical Pharmacokinetics of Metformin

The management of diabetes in indigenous Australians from primary care.

Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations.

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.

Metformin kinetics in healthy subjects and in patients with diabetes mellitus.

Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand.

Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National Health and Nutrition Examination Survey, 1999-2006.

The National Health and Medical Research Council Road Map: a strategic framework for improving Aboriginal and Torres Strait Islander health through research.

Metformin therapy in patients with chronic kidney disease.

P304

617-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12525

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Carl M. Kirkpatrick

Jerry R Greenfield

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25291501

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4386946

http://www.w3.org/2001/XMLSchema#string